FCGRT and autoimmune disease: FcRn inhibitors demonstrate a rapid onset of action, producing dose-dependent reductions in total IgG levels within days, which frequently correlates with early clinical improvement, making FcRn inhibition a targeted, less invasive alternative to plasma exchange (PLEX) in the treatment of IgG-mediated autoimmune diseases.